Rapastinel Trifluoroacetate (GLYX-13 Trifluoroacetate) is an NMDA receptor modulator with glycine-site partial agonist properties. Rapastinel Trifluoroacetate has the potential for major depressive disorder treatment.
CAT No: R1803
CAS No:1435786-04-1
Synonyms/Alias:Rapastinel Trifluoroacetate;1435786-04-1;GLYX-13 trifluoroacetate;Rapastinel (Trifluoroacetate);(2S)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide;2,2,2-trifluoroacetic acid;Rapastinel TFA salt;GLYX-13 TFA salt;RapastinelTrifluoroacetate;BCWVNVCGYWOAAK-GDLIIDCZSA-N;GLXC-03841;HY-16728B;AKOS040758824;RAPASTINEL; TRIFLUOROACETIC ACID;DA-77350;MS-29761;CS-0040824;GLYX-13 trifluoroacetate, >=98% (HPLC);G14102;
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.